Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0699790 (
colon cancer
)
28,837
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study investigated the expression and clinical significance of
flavin-containing monooxygenase 5
(
FMO5
) in colorectal cancer (CRC). The expression of
FMO5
was detected by immunohistochemistry in 208
colon cancer
tissues and 8 normal colon tissues. Then, the correlations of
FMO5
expression with several clinicopathological features were evaluated.
FMO5
mRNA expression from The Cancer Genome Atlas dataset was assessed for further validation. In addition, the association of the expression of
FMO5
with prognosis was further evaluated by Kaplan-Meier survival curves and Cox proportional hazards model. The FMO5 protein level in
colon cancer
tissues was significantly higher than that in normal colon tissues (P<0.001). Overexpression of
FMO5
was associated with an advanced clinical stage of cancer (P=0.018) and lymph node metastasis (P=0.03). The TCGA dataset also demonstrated that
FMO5
was upregulated in CRC with advanced clinical stage (P=0.047), lymph node metastasis (P=0.045) and distant metastasis (P=0.030). The Kaplan-Meier survival curves showed that higher
FMO5
mRNA indicated a shorter overall survival in patients with CRC compared with a low expression of
FMO5
(P=0.029). Cox proportional hazards regression revealed that a high
FMO5
mRNA level served as an independent prognostic factor for patients with CRC (hazard ratio, 2.865; 95% confidence interval, 1.116-7.355; P=0.029). A high expression of
FMO5
may serve roles in colorectal carcinogenesis and distant metastasis.
FMO5
may be an independent predictive factor for the prognosis of CRC.
...
PMID:Overexpression of flavin-containing monooxygenase 5 predicts poor prognosis in patients with colorectal cancer. 2945 41
